|Awarded On||February 18, 2015|
|Title||Mechanisms of de novo and acquired resistance to therapeutic treatment of bone-metastatic prostate cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Gary Gallick|
Many new therapeutics have been approved that prolong the lives of men who have prostate cancer that has metastasized to the bone. However, the effects of these drugs are often short-lived, and tumor cells that are resistant to the therapy regrow, leading to death of the patient. If the mechanisms by which resistance develops were better understood, new drugs or drug combinations may be developed that would delay or prevent therapy resistance. Our studies have focused on mechanisms of resistance with the goal of developing such efficacious drug combinations. An unusual property of prostate cancer bone metastases is that they promote the formation of new bone. In doing so, tumors interacting ...